Latest News and Press Releases

AscellaHealth Service and Infrastructure Enhancements Support Specialty Drug Manufacturers

Bio Usawa Biotechnology Ltd. and Bioeq AG today announced a partnership to bring a life-changing biosimilar of ranibizumab to Sub-Saharan Africa.

Boston, June 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Biosimilars: Global Markets” is expected to grow from $28.5 billion in 2024 to $69.2 billion by the end of...

R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its partnership with Microsoft,...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April...

AscellaHealth Honored as Silver Stevie® Award Winner in 2025 American Business Awards®

AscellaHealth Releases Q1 2025 Specialty & Rare Pipeline Digest™ Providing Essential Clinical Drug Updates

Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.

AscellaHealth announces the appointment of two senior leaders: Clayton Edwards, RPh, MBA and Carl T. Bertram, PharmD, MS, MBA

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of...